Can-Fite BioPharma (CANF) Cash & Equivalents (2013 - 2025)

Can-Fite BioPharma (CANF) has 13 years of Cash & Equivalents data on file, last reported at $8.5 million in Q4 2025.

• Quarterly Cash & Equivalents rose 76.97% year-over-year to $8.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.5 million (up 76.97% YoY) and the FY2025 annual result came in at $8.5 million, up 76.97% from the prior year.
• Cash & Equivalents improved to $8.5 million in Q4 2025, from $6.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $8.5 million in Q4 2025 to a low of $1.0 million in Q2 2021.
• A 5-year average of $4.1 million and a median of $4.0 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents plunged 88.69% — and 2023, when it jumped 101.99%.
• Tracing CANF's Cash & Equivalents over 5 years: stood at $4.4 million in 2021, then slumped by 32.16% to $3.0 million in 2022, then surged by 43.65% to $4.3 million in 2023, then rose by 12.79% to $4.8 million in 2024, then jumped by 76.97% to $8.5 million in 2025.
• The last three Cash & Equivalents figures came in at $8.5 million (Q4 2025), $6.5 million (Q2 2025), and $4.8 million (Q4 2024), per Business Quant data.